Immucell Corp /De/ financial data

Symbol
ICCC on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
56 Evergreen Dr, Portland, ME
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 290 % -3.29%
Quick Ratio 165 % -11.8%
Debt-to-equity 71 % +8.38%
Return On Equity -8.46 % +61.2%
Return On Assets -4.94 % +62.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.98M shares +15.9%
Common Stock, Shares, Outstanding 8.98M shares +15.8%
Entity Public Float 30.6M USD -1.7%
Common Stock, Value, Issued 904K USD +15.7%
Weighted Average Number of Shares Outstanding, Basic 8.17M shares +5.42%
Weighted Average Number of Shares Outstanding, Diluted 8.17M shares +5.42%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.01M USD +11.4%
Revenue from Contract with Customer, Excluding Assessed Tax 5.4M USD +12.5%
Research and Development Expense 3.9M USD -11.3%
Selling and Marketing Expense 3.47M USD +12.2%
General and Administrative Expense 2.22M USD +3.85%
Operating Income (Loss) -1.64M USD +71.5%
Nonoperating Income (Expense) -125K USD -151%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.15M USD +62.8%
Income Tax Expense (Benefit) 10.1K USD +117%
Net Income (Loss) Attributable to Parent -2.16M USD +62.7%
Earnings Per Share, Basic -0.26 USD/shares +65.3%
Earnings Per Share, Diluted -0.26 USD/shares +65.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.32M USD
Accounts Receivable, after Allowance for Credit Loss, Current 3.77M USD +72.6%
Inventory, Net 7.11M USD -8.95%
Other Assets, Current 57.7K USD -24.8%
Assets, Current 15M USD +31.2%
Property, Plant and Equipment, Net 25.3M USD -8.08%
Operating Lease, Right-of-Use Asset 4.56M USD -0.23%
Intangible Assets, Net (Excluding Goodwill) 43K USD -30.8%
Goodwill 95.6K USD 0%
Other Assets, Noncurrent 33.4K USD -42.1%
Assets 45.1M USD +2.95%
Liabilities, Current 4.41M USD +5.12%
Long-term Debt and Lease Obligation 9.04M USD -14.2%
Operating Lease, Liability, Noncurrent 4.13M USD +1.28%
Liabilities 17.6M USD -6.55%
Retained Earnings (Accumulated Deficit) -14.2M USD -18%
Stockholders' Equity Attributable to Parent 27.5M USD +10.1%
Liabilities and Equity 45.1M USD +2.95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 419K USD
Net Cash Provided by (Used in) Financing Activities -367K USD -149%
Net Cash Provided by (Used in) Investing Activities -70.4K USD +89.7%
Common Stock, Shares Authorized 15M shares 0%
Common Stock, Shares, Issued 9.04M shares +15.7%
Common Stock, Par or Stated Value Per Share 0.1 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.76M USD +284%
Interest Paid, Excluding Capitalized Interest, Operating Activities 136K USD +55%
Deferred Tax Assets, Valuation Allowance 4.59M USD +13.9%
Operating Lease, Liability 4.56M USD -3.39%
Depreciation 2.67M USD -1.11%
Payments to Acquire Property, Plant, and Equipment 70.4K USD -89.7%
Lessee, Operating Lease, Liability, to be Paid 7.73M USD -6.95%
Property, Plant and Equipment, Gross 46.4M USD +0.72%
Operating Lease, Liability, Current 432K USD -32.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 350K USD +2%
Lessee, Operating Lease, Liability, to be Paid, Year One 712K USD -24.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -14.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.17M USD -11.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 357K USD +2%
Deferred Tax Assets, Operating Loss Carryforwards 3.71M USD -0.63%
Current Income Tax Expense (Benefit) 8.43K USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 364K USD +2%
Operating Lease, Payments 577K USD +132%
Additional Paid in Capital 36.2M USD +0.9%
Amortization of Intangible Assets 19.1K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 326K USD -11.7%
Interest Expense 585K USD +40.3%